NCT07711899Not yet recruiting
Plasma Taurine in Older Women With Obesity: Impact of Metabolic Phenotype and Combined Exercise
Plasma Taurine Concentrations in Older Women With Obesity: The Influence of Metabolic Phenotype and Combined Exercise Training
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
Population aging has been accompanied by a rise in obesity and other chronic diseases, increasing cardiovascular risk particularly among women, who exhibit a higher prevalence in older age groups compared to men. Aging and obesity share pathophysiological mechanisms, such as chronic inflammation and oxidative stress. However, distinct obesity phenotypes exist, such as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Consequently, therapeutic interventions involving nutritional strategies and physical training are highly relevant, especially for older women. Taurine, a sulfur-containing amino acid, plays a role in modulating oxidative stress, inflammation, osmoregulation, and mitochondrial function. Rationale: Plasma taurine concentrations are lower in women with obesity compared to healthy individuals. However, studies investigating these concentrations across different phenotypes-particularly in older women, a group susceptible to functional and metabolic changes-remain limited. Understanding these variations could clarify taurine's role in the pathophysiology of obesity and aging and inform personalized therapeutic strategies. Combined physical training stands out as an effective strategy for modulating inflammatory, oxidative, and metabolic pathways, in addition to improving psychosocial aspects. Given that taurine levels can be influenced by these pathways, investigating the taurine response to physical training across different metabolic phenotypes may contribute to developing low-cost interventions aimed at improving the quality of life for older women with obesity.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of Sao Paulo
- Diseases
- Obesity
- NCT number
- NCT07711899
What you commit to
- Study type: Interventional
- Planned participants: 36
- From 1 Oct 2026 to the primary completion date, 1 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous diagnosis of:
- Neoplasms;
- Autoimmune diseases;
- Hepatic diseases;
- Coronary diseases;
- Renal diseases;
- Neurodegenerative diseases;
- Infectious diseases.
- Previous or ongoing treatments
- Medication use
- Hypoglycemic agents
- Insulin (Bell, Kivimäki, \& Hamer, 2014).
Other illness
- Clinical conditions
- Use of medication for thyroid disorders.
Other
- Contraindication to physical exercise.
- Participation in exercise training programs, nutritional counseling, or weight loss treatment within the 3 months preceding the intervention.
- Lifestyle habits
- Current smoking.
- Alcohol consumption.
- For MHO Group:
- Protocol adherence \*Attendance at less than 80% of the training sessions (De Carvalho et al., 2021).
Who the study is looking for
- Women aged 60 to 75 years.
- Residents of the city or region of Ribeirão Preto, São Paulo, Brazil.
- Physically inactive for at least 3 months.
- Body mass index (BMI) ≥ 30 kg/m² (PAHO, 2002).
- Body fat percentage ≥ 35%, according to obesity diagnostic criteria (Batsis et al., 2016; Rubino et al., 2025).
- Classified into one of two obesity phenotypes based on Zembic et al. (2021):
- Metabolically Healthy Obesity (MHO/OMS): all of the following criteria must be met:
- Systolic blood pressure (SBP) \< 130 mmHg;
- Waist-to-hip ratio \< 0.95;
- Fasting blood glucose \< 126 mg/dL.
- Metabolically Unhealthy Obesity (MUO/OMNS): meets two or fewer of the above criteria.
Age in the registry: 60 years to 75 years · Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.